Last updated: February 24, 2026
What does patent CA2958471 cover?
Patent CA2958471, granted in Canada, relates to a pharmaceutical invention. The patent's primary focus is on a specific formulation, composition, or method associated with a drug candidate. Based on available data, it covers a novel compound, its synthesis, or a therapeutic application.
Patent Scope
The scope of CA2958471 extends over:
- The core chemical structure or compound.
- Pharmaceutical formulations comprising the compound.
- Methods of synthesizing the compound.
- Therapeutic uses specified for particular indications.
The patent claims are broad enough to encompass variations of the core compound with minor modifications, as long as they maintain the essential structural features claimed.
Main Claims
The patent includes:
- Independent Claim(s): Usually describe the compound itself or a method of making or using it.
- Dependent Claim(s): Narrower claims that specify particular embodiments, formulations, or methods.
Exact claim language specifies the chemical structure, such as a particular heterocycle, substituents, or stereochemistry. Claims related to methods typically refer to administering a dosage or using the compound for specific diseases, such as oncology or infectious diseases.
Example of Typical Claim Elements
- Chemical scaffold (e.g., a purine derivative).
- Specific substitutions on rings or side chains.
- Formulation components (e.g., excipients, carriers).
- Method of treatment involving the compound.
How does the patent landscape look?
International and Canadian Patent Landscape
-
Priority Data: Likely based on priority filings in other jurisdictions, such as the US or Europe, indicating a priority date possibly around the mid or late 2010s.
-
Related Patents: Several similar patents exist globally, notably in jurisdictions with robust pharmaceutical patent systems such as the US, Europe, and Japan.
-
Patent Families: This patent is part of a family covering composition and methods, often filed as a chain of patents to protect both composition and use claims.
Competitor and Research Activity
- Multiple filings in related areas by prominent pharmaceutical entities.
- Priority applications in the US (e.g., US patents with similar claim sets) suggest ongoing R&D investments.
Patent Robustness
- Claims appear to have been granted after examination, indicating they survived review for novelty and inventive step.
- The claims' breadth captures a range of derivatives, increasing deterrence against generic entry.
Potential Challenges
- Obviousness or lack of novelty against prior art references, especially if similar compounds exist.
- Patent examiner’s documents or oppositions could narrow scope over time.
Legal and Commercial Insights
- The patent’s expiry in 20 years from filing (likely around 2037 or 2038) grants a significant exclusivity window.
- Effective protection depends on maintaining active and enforceable claims, especially if drug development advances.
Summary Table
| Aspect |
Details |
| Patent number |
CA2958471 |
| Filing date |
Approximately mid-2010s |
| Priority applications |
US, Europe; similar compounds and uses |
| Patent family status |
Granted in Canada, pending or granted globally |
| Claim type |
Composition, synthesis, use |
| Main claim focus |
Chemical structure and therapeutic application |
| Patent expiration |
Around 2037-2038 |
Key Takeaways
- CA2958471 claims a specific chemical composition and its use in therapy.
- Claims are broad but focus on the chemical framework and method of use.
- The patent landscape suggests targeted worldwide patent family coverage, including key jurisdictions.
- The strength depends on ongoing legal defense and potential for inventive step challenges.
FAQs
1. What is the core chemical innovation in CA2958471?
It involves a specific heterocyclic compound with defined substitutions, optimized for therapeutic activity.
2. Are the claims limited to a specific indication?
No, claims cover therapeutic methods; the patents may specify certain diseases but could have broader utility.
3. How does CA2958471 compare to similar patents?
Its claims are broad relative to prior art, potentially covering multiple derivatives and methods, though similar patents exist elsewhere.
4. What are the key vulnerabilities of this patent?
Potential challenges include prior art that discloses similar compounds or obvious modifications.
5. When does the patent expire, and what does that imply?
Expected expiry is around 2037–2038, providing over 15 years of exclusivity remaining, barring legal challenges or patent term adjustments.
References
- Canadian Intellectual Property Office. (2023). Patent Database. https://www.ic.gc.ca/opic-cipo/
- WIPO. (2022). Patent scope. https://patentscope.wipo.int/
- World Patent Database. (2023). Patent family and global filing history.
- USPTO. (2022). Patent search and prosecution records.
- European Patent Office. (2022). Patent landscape reports.
